川芎嗪治疗胎儿宫内生长迟缓改善子宫胎盘胎儿血液循环的研究  

The Study of Ligustrazine in Improving the Utero-placental-fetal Circulation in the Treatment of Intrauterine Growth Retradation

作　　者：许建平[1] 马庭元[1] 闻良珍[1] 张友耿[2] 张青萍[2] 高淑英[2] 

机构地区：[1]同济医科大学附属同济医院妇产科,武汉430030 [2]同济医科大学附属同济医院超声室,武汉430030

出　　处：《华中科技大学学报（医学版）》1998年第4期300-302,308,共4页Acta Medicinae Universitatis Scientiae et Technologiae Huazhong

基　　金：国家自然科学基金!38970735

摘　　要：应用中药川芎嗪等治疗58例胎儿宫内生长迟缓（IUGR）患者，分为川芎嗪治疗组47例、氨基酸治疗组11例。结果显示治疗后IUGR的病理生理变化接近或恢复正常，脐动、静脉及子宫动脉的TAV和Q上升，S／D值、RI等下降；母血E3、HPL上升，6-keto-PGF1a水平增高，TXB2／6-keto-PGF1a比值下降，川芎嗪组治疗总有效率达95．74％，显著优于氨基酸组（81．82％），P＜0．05，差异有显著性意义。研究表明川芎嗪能改善胎盘功能，纠正子宫胎盘胎儿血液循环障碍，是治疗IUGR的有效药物。Traditional Chinese medicine Ligustrazine was used to treat 58 cases of intrauterine growthretardation (IUGR). The patients were divided into Ligustrazine group (LIG ), 47 cases and amino-uacid group(AAG), 11 cases. The results showed that after treatment, all the pathophysiology changes were returnedto or near the normal range: Time average velosity (TAV) and blood flow volume (Q) of umbilical artery(UmA), umbilical vein(UmV) and uterine artery(UtA) were increased; PI, RI, S/D ratios of UmA andUtA were markedly reduced to normal level; Maternal serum E3, HPL and 6-keto-PGF1a (6KP) levels wereincreased to normal range; TXB2/6KP ratio was reduced. The result of treatment in LIG was better thanthat in AAG. The fetal outcome showed that total effective rate was 95. 47% in LIG, being significantlyhigher than that in AAG (81. 82% ),p<0. 05. This study shows that Ligustrazine might improve the uteroplacental circulation (UPFC) and correct UPFC disturbance, being an effective drug in treating IUGR.

关 键 词：川芎嗪 胎儿生长迟缓 

分 类 号：R285[医药卫生—中药学]